Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement
Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement
复制标题
DOI：
10.1186/ar1826
复制
发表时间：
2005-01-01
影响因子：
4.9
通讯作者：
Kishimoto, T
中科院分区：
文献类型：
--
作者：
Woo, P;Wilkinson, N;Kishimoto, T
18 名白人（白人、中东和亚洲）儿童被英国和法国的儿科风湿病专家诊断为患有系统性幼年特发性关节炎 (sJIA)，他们被纳入这项开放标签、单剂量试验。所有患者在入组前接受 >0.2 mg/kg/天的泼尼松龙或其等效物时，都有持续症状和疾病活动至少三个月的证据。 12 名患者还接受了甲氨蝶呤治疗（= 50% 改善。随年龄变化没有可观察到的差异。观察这些儿童的临床改善长达八周，支持这样的假设：IL-6 是 sJIA 炎症过程中关键基因上调的关键细胞因子，并且需要考虑 MRA 在血管外隔室中隔离的可能性。
Eighteen Caucasian (white, Middle East and Asian) children diagnosed by paediatric rheumatologists in the UK and France as having systemic juvenile idiopathic arthritis (sJIA) were enrolled in this open label, single dose trial. All patients had evidence of continued symptoms and disease activity for at least three months while receiving >0.2 mg/kg/day of prednisolone, or its equivalent, prior to recruitment. Twelve patients also received methotrexate (= 50% improvement. There were no observable differences with age. Clinical improvement in these children was observed for up to eight weeks, supporting the hypothesis that IL-6 is a key cytokine in the upregulation of genes crucial in the inflammation processes of sJIA, and the possibility of sequestration of MRA in the extra-vascular compartment needs to be considered.